Magnetic Resonance Imaging or Endoscopic Ultrasonography for Detection and Surveillance of Pancreatic Neuroendocrine Neoplasms in Patients with Multiple Endocrine Neoplasia Type 1?

Abstract

Our aim was to compare the clinical utility of Magnetic Resonance Imaging (MRI) and Endoscopic Ultrasonography (EUS) in identifying Pancreatic Neurondocrine Neoplasms (PanNENs) and monitoring size alterations in Multiple Endocrine Neoplasia type 1 (MEN1) patients. Thirty-one MEN1 patients with PanNENs and concurrent screening by EUS and abdominal MRI were included and 129 pancreatic lesions were detected in total. MRI detected fewer lesions than EUS (n=73 vs. 110, p=0.006). MRI sensitivity and specificity compared to EUS at 20 and 10 mm cut-offs of maximal lesion diameter were 96 and 88% (20 mm cut-off) and 90 and 82%(10 mm cut-off), respectively (concordance rates of 97 and 87% and Cohen’s kappa=0.912 and 0.718, respectively). Lesions<1 cm were more often detected with EUS (p=0.025). Data from sequential concurrent imaging on lesion growth rate [n=7 (mean±SD: 2 mm/year±3.4 mm vs. 1.9 mm/year±3.6 mm)] over a period of at least two years as well as pathology data in connection to preoperative concurrent imaging were available in a small number of patients (n=7, p=0.933 for mean differences in maximal lesion diameter). MRI of the pancreas was more readily available and less expensive than EUS in an outpatient setting. In conclusion, MRI performs well compared to EUS for the detection and subsequent surveillance of MEN1-related panNENs larger than 10 mm and seems to be cost-effective. Both modalities could be used at initial assessment and MRI alone could be utilized thereafter in patient surveillance. EUS retains its value in surgical planning and the detection of small mostly functional PanNENs.

Key words

multiple endocrine neoplasia type 1 - neuroendocrine tumor - magnetic resonance imaging - endoscopic ultrasonography

^§ Institute where the investigations have been carried out: 1st Department of Propaupedic Internal Medicine, Endocrine Oncology Unit, Laiko Hospital, National and Kapodistrian University of Athens, Greece.

• References

• 1 Thakker RV. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 2000; 29: 541-567
• 2 Trump D, Farren B, Wooding C. et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996; 89: 653-669
• 3 Shepherd JJ. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized?. Arch Surg 1991; 126: 935-952
• 4 Ito T, Igarashi H, Uehara H. et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: A prospective study: Comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013; 92: 135-181
• 5 Falconi M, Eriksson B, Kaltsas G. et al. Vienna Consensus Conference p. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171
• 6 Manoharan J, Raue F, Lopez CL. et al. Is Routine screening of young asymptomatic MEN1 patients necessary?. World J Surg 2017; 41: 2026-2032
• 7 Brandi ML, Gagel RF, Angeli A. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671
• 8 Triponez F, Dosseh D, Goudet P. et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243: 265-272
• 9 Ekeblad S, Skogseid B, Dunder K. et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803
• 10 Vinik AI, Woltering EA, Warner RR. et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39: 713-734
• 11 Triponez F, Goudet P, Dosseh D. et al. Is surgery beneficial for MEN1 patients with small (<or=2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662 discussion 663–654
• 12 Thakker RV, Newey PJ, Walls GV. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
• 13 Berrington de Gonzalez A, Mahesh M. et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169: 2071-2077
• 14 Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008; 81: 362-378
• 15 Barbe C, Murat A, Dupas B. et al. Magnetic resonance imaging vs.endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 2012; 44: 228-234
• 16 Camera L, Paoletta S, Mollica C. et al. Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: Multidetector-row computed tomography vs. endoscopic ultrasound. Radiol Med 2011; 116: 595-606
• 17 Kann PH, Kann B, Fassbender WJ. et al. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): Least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006; 114: 361-365
• 18 Cohen JF, Korevaar DA, Altman DG. et al. STARD 2015 Guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. BMJ Open 2016; 6: e012799
• 19 Krouwer JS. Why Bland-Altman plots should use X, not (Y+X)/2 when X is a reference method. Stat Med 2008; 27: 778-780
• 20 James PD, Tsolakis AV, Zhang M. et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: A meta-analysis. Gastrointest Endosc 2015; 81: 848-856 e841
• 21 Polenta V, Slater EP, Kann PH. et al. Preoperative imaging overestimates the tumor size in pancreatic neuroendocrine neoplasms associated with multiple endocrine neoplasia type 1. World J Surg 2018; 42: 1440-1447
• 22 Lewis MA, Thompson GB, Young Jr. WF. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 2012; 36: 1375-1381
• 23 Kann PH, Balakina E, Ivan D. et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: An endoscopic ultrasound imaging study. Endocr Relat Cancer 2006; 13: 1195-1202
• 24 van Asselt SJ, Brouwers AH, van Dullemen HM. et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc 2015; 81: 159-167 e152
• 25 Sahani DV, Bonaffini PA, Fernandez-Del Castillo C. et al. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology 2013; 266: 38-61
• 26 Kann PH. Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors?. Rev Endocr Metab Disord 2018; 19: 133-137
• 27 O'Toole D, Palazzo L, Arotcarena R. et al. Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest Endosc 2001; 53: 470-474
• 28 Deppen SA, Liu E, Blume JD. et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med 2016; 57: 708-714
• 29 Albers MB, Librizzi D, Lopez CL. et al. Limited value of Ga-68-DOTATOC-PET-CT in routine screening of patients with multiple endocrine neoplasia type 1. World J Surg 2017; 41: 1521-1527
• 30 Antwi K, Fani M, Heye T. et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: Evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imaging 2018; 45: 2318-2327